Veracyte, Inc.
VCYT
Peringkat dalam Saham
#4357
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Harga Saham
$44.93
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$3.61B
Perubahan (1 hari)
2.57%
Perubahan (1 tahun)
24.45%
Negara
US
Perdagangan Veracyte, Inc. (VCYT)
Kategori
Healthcare
Rasio P/S untuk Veracyte, Inc. (VCYT)
Rasio P/S per October 2026 TTM: 6.22
Menurut laporan keuangan dan harga saham terbaru dari Veracyte, Inc., rasio P/S saat ini (TTM) adalah 6.22. Pada akhir 2023, rasio P/S perusahaan adalah 5.54.
Riwayat rasio P/S untuk Veracyte, Inc. dari 2011 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 6.22 | -8.32% |
| 2024 | 6.79 | 22.75% |
| 2023 | 5.54 | -3.33% |
| 2022 | 5.73 | -55.07% |
| 2021 | 12.74 | -42.55% |
| 2020 | 22.18 | 107.23% |
| 2019 | 10.70 | 111.43% |
| 2018 | 5.06 | 64.40% |
| 2017 | 3.08 | -10.20% |
| 2016 | 3.43 | -9.14% |
| 2015 | 3.77 | -31.06% |
| 2014 | 5.47 | 98.64% |
| 2013 | 2.76 | -82.96% |
| 2012 | 16.18 | -77.25% |
| 2011 | 71.11 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 5.37 | -13.70% |
US
|
|
| 6.29 | 1.08% |
US
|
|
| 21.02 | 237.66% |
US
|
|
| - | - |
CN
|
|
| 6.67 | 7.09% |
US
|
